Skip to main content
NewslettersWatchlist

Johnson & Johnson(JNJ-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low155.15
Day High155.15
Open:155.15
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

Lawyers increase talc ad spending after Johnson & Johnson’s $9-billion settlement offer

Data show plaintiffs’ lawyers spent more than $778,000 to air more than 4,600 TV ads soliciting the claims, the most spent on talc ads since August, 2023, according to X Ante founder Rustin Silverstein
Motley Fool
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
Stock Target Advisor
What’s The Best Portfolio For a Trump Presidency?
MarketBeat
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Reuters
Lawyers increase talc ad spending after Johnson & Johnson’s $9-billion settlement offer
Barchart
1 Outstanding AI Growth Stock to Grab Now
Motley Fool
3 Dividend Growth Stocks You Can Buy and Hold Forever
Motley Fool
Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government
Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
Motley Fool
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Motley Fool
All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year
Motley Fool
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
Motley Fool
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
Motley Fool
This Magnificent Dividend Stock Is as Healthy as It Gets
Stock Target Advisor
Top Stock News: October 16th, 2024
MarketBeat
Johnson & Johnson Stock: Setting the Stage for 2025 Highs
Motley Fool
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
Motley Fool
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
The Globe and Mail
Market movers: Stocks seeing action on Tuesday - and why
Baystreet
Stocks Down to Begin Short Week
SYNDTGAM
Johnson & Johnson lifts profit and sales forecasts, exceeds Wall Street expectations
Stock Target Advisor
What to Expect from Johnson & Johnson’s Q3 Earnings Report
Barchart
S&P Futures Tread Water Ahead of Fed Speak and More Big Bank Earnings

Profile

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.